Journal article
Moving forward in clinical research with master protocols
Abstract
With billions of dollars in research and development (R&D) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. In …
Authors
Park JJH; Dron L; Mills EJ
Journal
Contemporary Clinical Trials, Vol. 106, ,
Publisher
Elsevier
Publication Date
July 2021
DOI
10.1016/j.cct.2021.106438
ISSN
1551-7144